12 Dez 2022 | Press release
TechnoPhage announced that it has provided TP-102, developed for the treatment of infected diabetic foot ulcers, for two compassionate use cases, which took place in July 2022, in Israel. The product was recently evaluated in the scope of the Phase I/IIa clinical...
23 Set 2022 | Press release
TechnoPhage announced the spin-off of T-Oncology AG, which will focus on the development of Antibody Drug Conjugates (ADCs), based on the proprietary Small Domain Antibodies platform (TechnoBodies), for the treatment of cancer. TechnoBodies technology has been...